₹55.14
+1.17% today
· 30d +1.68%
as of 2026-09-04
Price · Daily Candles
“KREBSBIO struggles with profitability amid declining revenue; short-term technicals suggest reprieve.”
KREBSBIO is navigating a challenging financial landscape, marked by a significant annual revenue decline of 45.21% and a substantial net loss of ₹17 Cr for the fiscal year 2026. Despite a quarterly revenue increase of 11.62% YoY and a quarterly operating profit of ₹1 Cr, the company remains free cash flow negative at -₹6 Cr. The stock currently trades at -0.87x Price-to-Book, reflecting deep negative book value.
BULL CASE
+Quarterly revenue shows a positive YoY trend, increasing by 11.62% in Q4 2026 to ₹7 Cr.
+Operating profit margin for Q4 2026 saw a substantial increase of 91.63% YoY, reaching 12.89%.
+Current technical indicators MACD and RSI(14) are both moderately bullish, suggesting short-term price momentum.
+The stock has seen a 1-month return of 9.39% and a 1-week return of 12.09%.
BEAR CASE
−Annual revenue witnessed a sharp decline of 45.21% in FY26 to ₹24 Cr, and 3-year revenue CAGR is -23.38%.
−Company reported a net loss of -₹17 Cr annually and -₹2 Cr quarterly, with an EPS of -₹1.09.
−KREBSBIO remains free cash flow negative at -₹6 Cr for FY26, resulting in an intrinsic value not being applicable.
−The stock is trading 42.82% below its 52-week high of ₹113.5, with a 1-year return of -13.77%.
−ML predictions for 1-year FCF growth show weak ranks across all horizons (recent 2-year: 0.327, rolling 4-year: 0.212, stable 7-year: 0.133).
⟳ What Changed
₹ Latest Earnings · Q ending 2026-06-30
REVENUE
₹7 Cr
+27.42% YoY
NET PROFIT
₹-2 Cr
OPM
13.77%
+51.56pp YoY
EPS
₹-1.15
Intrinsic value · DCF: N/A — Company is currently free-cash-flow negative (-5.0% of mktcap). DCF assumes a going concern generating positive cash flow; a meaningful intrinsic value can only be computed once FCF turns positive. Use the Strategy Fit and ML sections instead.
◇ Sector Position
KREBSBIO, with its negative PB ratio of -0.87, significantly underperforms peers like SUNPHARMA (PE 40.41, ROCE 22.46%) and DIVISLAB (PE 69.81, ROCE 21.47%), which exhibit strong profitability and market valuations.
PEERPEROCE %
KREBSBIO——
+ 2 more peers — sign in to view
ML Forward Growth Predictions 🔒
37
SCORE / 100
Overall
6-axis composite of the sections below.
Performance
UNDERPERFORMER
20
Valuation
—
—
Growth
DECLINING
22
Profitability
DECENT
55
Technicals
WEAK
40
Risk
MODERATE
50
Key Stats
P/B
-0.87
52W HIGH
₹82.49
OFF HIGH
-33.16%
MKT CAP
₹119 Cr
◉ Active Signals
MACDNeutral0.0883
RSI(14)Neutral49.21
⧉ Strategy Fit 🔒